Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OGI Stock Forecast 2026-2027
$0.87
Current Price
$125.32M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to OGI Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
OGI Price Momentum
-10.3%
1 Week Change
-12.1%
1 Month Change
-40.4%
1 Year Change
-48.2%
Year-to-Date Change
-61.1%
From 52W High of $2.24
+2.1%
From 52W Low of $0.85
📊 TOP ANALYST CALLS
Did OGI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Organigram is one of their latest high-conviction picks.
Latest OGI Stock Price Targets & Analyst Predictions
OGI has shown a year-to-date change of -48.2% and a 1-year change of -40.4%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for OGI. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OGI Analyst Ratings
4
Buy
1
Hold
0
Sell
OGI Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.87
Latest OGI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OGI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 17, 2023 | Stifel | Andrew Partheniou | Buy | Maintains | $4.00 |
| May 11, 2021 | CIBC | John Zamparo | Neutral | Upgrade | $N/A |
| Apr 14, 2021 | CIBC | John Zamparo | Underperformer | Downgrade | $3.25 |
| Mar 10, 2021 | BMO Capital | Underperform | Downgrade | $N/A | |
| Jan 9, 2020 | Raymond James | Market Perform | Downgrade | $N/A | |
| Nov 12, 2019 | BMO Capital | Market Perform | Downgrade | $N/A | |
| Oct 11, 2019 | Jefferies | Buy | Upgrade | $N/A | |
| Feb 25, 2019 | Jefferies | Buy | Initiates | $N/A |
Organigram Global Inc. (OGI) Competitors
The following stocks are similar to Organigram based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Organigram Global Inc. (OGI) Financial Data
Organigram Global Inc. has a market capitalization of $125.32M with a P/E ratio of 9.9x. The company generates $195.05M in trailing twelve-month revenue with a -9.2% profit margin.
Revenue growth is -8.9% quarter-over-quarter, while maintaining an operating margin of -16.4% and return on equity of -5.9%.
Valuation Metrics
Market Cap
$125.32M
Enterprise Value
$129.98M
P/E Ratio
9.9x
PEG Ratio
-0.1x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
-8.9%
Gross Margin
+27.4%
Operating Margin
-16.4%
Net Margin
-9.2%
EPS Growth
-8.9%
Financial Health
Cash/Price Ratio
+4.1%
Current Ratio
2.8x
Debt/Equity
1.9x
ROE
-5.9%
ROA
-1.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Organigram Global Inc. (OGI) Business Model
About Organigram Global Inc.
What They Do
Produces and sells cannabis products in Canada.
Business Model
The company operates a vertically integrated model, generating revenue through the cultivation, manufacturing, and sale of a wide range of cannabis products for both medical and recreational use. It utilizes advanced cultivation techniques and has established a diverse product portfolio, which includes various forms of cannabis such as flowers, edibles, and concentrates, marketed under recognized brands.
Additional Information
Founded in 2010 and based in Toronto, Organigram is committed to quality and sustainability while expanding its global reach through strategic partnerships. It distributes its products through multiple channels including wholesale, retail, and online, and actively participates in regulatory advocacy and responsible consumption initiatives within the evolving cannabis industry.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,120
CEO
Mr. James H. Yamanaka
Country
Canada
IPO Year
2014
Website
www.organigram.caOrganigram Global Inc. (OGI) Latest News & Analysis
Latest News
Quick Summary
Organigram's Q2 earnings fell short, attributed to excessive harvests exceeding processing capacity. Negative organic growth is anticipated for H2 FY 2026, amid export issues and drying capacity bottlenecks.
Why It Matters
Organigram’s Q2 earnings miss highlights potential revenue declines, operational inefficiencies, and growth challenges, signaling risks for future performance and investor returns.
Source: Seeking Alpha
Market Sentiment:
Negative
Organigram Says Vape Weakness Pressures Margins
2 months ago
Quick Summary
Organigram Global Inc. (NASDAQ: OGI) reported weaker Q2 fiscal 2026 results, with declining sales in vape and infused pre-roll products impacting revenue and profitability.
Why It Matters
Weaker results from Organigram indicate declining demand in key product segments, potentially affecting future growth and profitability, which could lead to decreased investor confidence and stock performance.
Source: Benzinga
Market Sentiment:
Negative
Organigram Global Q2 Earnings Call Highlights
2 months ago
Quick Summary
Organigram (NASDAQ: OGI) reported a weaker Q2 for fiscal 2026, citing operational issues, slow growth in the Canadian cannabis market, and international flower specification challenges.
Why It Matters
Organigram's weaker Q2 results signal operational challenges and market softness, potentially impacting revenue and stock performance, raising concerns about future growth in the cannabis sector.
Source: MarketBeat
Market Sentiment:
Negative
Quick Summary
Organigram Global Inc. (OGI:CA) held its Q2 2026 earnings call, discussing its financial performance and future outlook. Further details are necessary for specific financial metrics.
Why It Matters
Organigram's Q2 2026 earnings reveal financial performance and growth potential, influencing stock valuation and investor sentiment in the cannabis sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Organigram Global Inc. reported Q2 Fiscal 2026 results: Gross Revenue of $93.3M (-9% YoY), Net Revenue of $59.8M (-9% YoY), and Adjusted EBITDA of $0.9M (-82% YoY).
Why It Matters
Organigram's declining revenues and drastically reduced adjusted EBITDA signal potential financial instability, raising concerns over future growth and profitability in the cannabis sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
OrganiGram (OGI) reported a quarterly loss of $0.01 per share, matching the Zacks Consensus Estimate, an improvement from a loss of $0.05 per share in the same period last year.
Why It Matters
OrganiGram's quarterly loss matching expectations signals stability, while the reduced loss from last year shows improvement, potentially boosting investor confidence in future profitability.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About OGI Stock
What is Organigram Global Inc.'s (OGI) stock forecast for 2027?
Analyst forecasts for Organigram Global Inc. (OGI) are not currently available. The stock is trading at $0.87.
Is OGI stock a good investment in 2027?
According to current analyst ratings, OGI has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OGI stock?
Price predictions from Wall Street analysts for OGI are not currently available. The stock is trading at $0.87.
What is Organigram Global Inc.'s business model?
The company operates a vertically integrated model, generating revenue through the cultivation, manufacturing, and sale of a wide range of cannabis products for both medical and recreational use. It utilizes advanced cultivation techniques and has established a diverse product portfolio, which includes various forms of cannabis such as flowers, edibles, and concentrates, marketed under recognized brands.
What is the highest forecasted price for OGI Organigram Global Inc.?
Price targets from Wall Street analysts for OGI are not currently available. The stock is trading at $0.87.
What is the lowest forecasted price for OGI Organigram Global Inc.?
Price targets from Wall Street analysts for OGI are not currently available. The stock is trading at $0.87.
What is the overall OGI consensus from analysts for Organigram Global Inc.?
The overall analyst consensus for OGI is bullish. Out of 3 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are OGI stock price projections?
Stock price projections, including those for Organigram Global Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:58 AM UTC